Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMW8QNG)

• Drug Name: Brolucizumab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Wet age-related macular degeneration	9B78.3Z	Approved	[1]
Diabetic macular edema	9B71.02	Phase 3	[2]

• Cross-matching ID: TTD Drug ID: DMW8QNG

Molecule-Related Drug Atlas

Drug(s) Targeting Vascular endothelial growth factor A (VEGFA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aflibercept	DMT3D5I	Central retinal vein occlusion with macular edema		Approved	[4]
Faricimab	DM83SEB	Diabetic macular edema	9B71.02	Approved	[5]
Ranibizumab	DMSYPNW	Central retinal vein occlusion with macular edema		Approved	[6]
Bevacizumab	DMSD1UN	Adenocarcinoma	2D40	Approved	[7]
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[8]
PTC299	DMP9TKE	Rheumatoid arthritis	FA20	Phase 2	[9]
RG7221	DM8J9DC	Colorectal cancer	2B91.Z	Phase 2	[10]
RO5520985	DMD3WNP	Colorectal cancer	2B91.Z	Phase 2	[11]
Abicipar pegol	DM59OJ2	Diabetic macular edema	9B71.02	Phase 2	[12]
MP0250	DMR3VCY	Non-small-cell lung cancer	2C25.Y	Phase 1/2	[13]

Drug(s) Targeting Vascular endothelial growth factor (VEGF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Squalamine	DM3PS2E	Solid tumour/cancer	2A00-2F9Z	Phase 3	[14]
PF-06439535	DMVHZDP	Non-small-cell lung cancer	2C25.Y	Phase 3	[15]
M710	DM1PRT6	Diabetic macular edema	9B71.02	Phase 3	[16]
FKB238	DM6R2XF	Non-small-cell lung cancer	2C25.Y	Phase 3	[17]
KSI-301	DMM2LTC	Diabetic macular edema	9B71.02	Phase 3	[18]
TRS003	DMM1VOH	Colorectal cancer	2B91.Z	Phase 3	[19]
MYL-1402O	DMXN2PP	Non-small-cell lung cancer	2C25	Phase 3	[20]
SB15	DMTOS6C	Neovascular age-related macular degeneration	9B78.3Z	Phase 3	[21]
Dilpacimab	DMCATH2	Solid tumour/cancer	2A00-2F9Z	Phase 2	[22]
ALG-1001	DMR2YPF	Diabetic macular edema	9B71.02	Phase 2	[23]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Vascular endothelial growth factor (VEGF)	TT9HKJA	VEGFA_HUMAN; VEGFB_HUMAN; VEGFC_HUMAN; VEGFD_HUMAN	Inhibitor	[3]
Vascular endothelial growth factor A (VEGFA)	TTOHSBA	VEGFA_HUMAN	Inhibitor	[1]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [2] ClinicalTrials.gov (NCT04058067) To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema (KINGLET). U.S. National Institutes of Health.
• [3] Brolucizumab: First Approval. Drugs. 2019 Dec;79(18):1997-2000.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [5] Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.
• [6] Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006 Oct;26(8):859-70.
• [7] FDA Approved Drug Products from FDA Official Website. 2004. Application Number: (ANDA) 125085.
• [8] Clinical pipeline report, company report or official report of Genentech (2009).
• [9] Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.J Neurooncol.2015 Jan;121(1):217-24.
• [10] Bispecific antibodies and their applications
• [11] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] Clinical pipeline report, company report or official report of Ohr Pharmaceutical.
• [15] National Cancer Institute Drug Dictionary (drug id 43234).
• [16] ClinicalTrials.gov (NCT03610646) Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea in Subjects With Diabetic Macular Edema. U.S. National Institutes of Health.
• [17] Clinical pipeline report, company report or official report of Fujifilm.
• [18] Clinical pipeline report, company report or official report of Kodiak Sciences.
• [19] Prevalence of porcine cysticercosis in Vellore, South India. Trans R Soc Trop Med Hyg. 2013 Jan;107(1):62-4.
• [20] MYL-1402O: A Bevacizumab Biosimilar. Target Oncol. 2022 Jan;17(1):85-88.
• [21] Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial. JAMA Ophthalmol. 2023 Jul 1;141(7):668-676.
• [22] Apoptogenic activity of 2alpha,3alpha-dihydroxyurs-12-ene-28-oic acid from Prunella vulgaris var. lilacina is mediated via mitochondria-dependent activation of caspase cascade regulated by Bcl-2 in human acute leukemia Jurkat T cells. J Ethnopharmacol. 2011 Jun 1;135(3):626-35.
• [23] Future therapies of wet age-related macular degeneration. J Ophthalmol. 2015;2015:138070.